Integrative molecular characterisation of gallbladder cancer reveals micro-environment-associated subtypes.
Aflatoxins
/ toxicity
Carcinogenesis
/ genetics
Carcinogens
/ toxicity
DNA Copy Number Variations
Female
Gallbladder Neoplasms
/ genetics
Gene Expression Profiling
Humans
Male
Middle Aged
Mutation
Neoplasm Staging
Survival Analysis
Transcriptome
Tumor Microenvironment
/ immunology
Tumor Suppressor Protein p53
/ genetics
Exome Sequencing
Aflatoxin
Gallbladder cancer
Immunogenomics
Micro-environment
Molecular subgroups
Journal
Journal of hepatology
ISSN: 1600-0641
Titre abrégé: J Hepatol
Pays: Netherlands
ID NLM: 8503886
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
15
05
2020
revised:
21
10
2020
accepted:
16
11
2020
pubmed:
5
12
2020
medline:
1
2
2022
entrez:
4
12
2020
Statut:
ppublish
Résumé
Gallbladder cancer (GBC) is the most common type of biliary tract cancer, but the molecular mechanisms involved in gallbladder carcinogenesis remain poorly understood. In this study, we applied integrative genomics approaches to characterise GBC and explore molecular subtypes associated with patient survival. We profiled the mutational landscape of GBC tumours (whole-exome sequencing on 92, targeted sequencing on 98, in total 190 patients). In a subset (n = 45), we interrogated the matched transcriptomes, DNA methylomes, and somatic copy number alterations. We explored molecular subtypes identified through clustering tumours by genes whose expression was associated with survival in 47 tumours and validated subtypes on 34 publicly available GBC cases. Exome analysis revealed TP53 was the most mutated gene. The overall mutation rate was low (median 0.82 Mut/Mb). APOBEC-mediated mutational signatures were more common in tumours with higher mutational burden. Aflatoxin-related signatures tended to be highly clonal (present in ≥50% of cancer cells). Transcriptome-wide survival association analysis revealed a 95-gene signature that stratified all GBC patients into 3 subtypes that suggested an association with overall survival post-resection. The 2 poor-survival subtypes were associated with adverse clinicopathologic features (advanced stage, pN1, pM1), immunosuppressive micro-environments (myeloid-derived suppressor cell accumulation, extensive desmoplasia, hypoxia) and T cell dysfunction, whereas the good-survival subtype showed the opposite features. These data suggest that the tumour micro-environment and immune profiles could play an important role in gallbladder carcinogenesis and should be evaluated in future clinical studies, along with mutational profiles. Gallbladder cancer is highly fatal, and its causes are poorly understood. We evaluated gallbladder tumours to see if there were differences between tumours in genetic information such as DNA and RNA. We found evidence of aflatoxin exposure in these tumours, and immune cells surrounding the tumours were associated with survival.
Sections du résumé
BACKGROUND & AIMS
Gallbladder cancer (GBC) is the most common type of biliary tract cancer, but the molecular mechanisms involved in gallbladder carcinogenesis remain poorly understood. In this study, we applied integrative genomics approaches to characterise GBC and explore molecular subtypes associated with patient survival.
METHODS
We profiled the mutational landscape of GBC tumours (whole-exome sequencing on 92, targeted sequencing on 98, in total 190 patients). In a subset (n = 45), we interrogated the matched transcriptomes, DNA methylomes, and somatic copy number alterations. We explored molecular subtypes identified through clustering tumours by genes whose expression was associated with survival in 47 tumours and validated subtypes on 34 publicly available GBC cases.
RESULTS
Exome analysis revealed TP53 was the most mutated gene. The overall mutation rate was low (median 0.82 Mut/Mb). APOBEC-mediated mutational signatures were more common in tumours with higher mutational burden. Aflatoxin-related signatures tended to be highly clonal (present in ≥50% of cancer cells). Transcriptome-wide survival association analysis revealed a 95-gene signature that stratified all GBC patients into 3 subtypes that suggested an association with overall survival post-resection. The 2 poor-survival subtypes were associated with adverse clinicopathologic features (advanced stage, pN1, pM1), immunosuppressive micro-environments (myeloid-derived suppressor cell accumulation, extensive desmoplasia, hypoxia) and T cell dysfunction, whereas the good-survival subtype showed the opposite features.
CONCLUSION
These data suggest that the tumour micro-environment and immune profiles could play an important role in gallbladder carcinogenesis and should be evaluated in future clinical studies, along with mutational profiles.
LAY SUMMARY
Gallbladder cancer is highly fatal, and its causes are poorly understood. We evaluated gallbladder tumours to see if there were differences between tumours in genetic information such as DNA and RNA. We found evidence of aflatoxin exposure in these tumours, and immune cells surrounding the tumours were associated with survival.
Identifiants
pubmed: 33276026
pii: S0168-8278(20)33820-4
doi: 10.1016/j.jhep.2020.11.033
pmc: PMC8058239
mid: NIHMS1650925
pii:
doi:
Substances chimiques
Aflatoxins
0
Carcinogens
0
TP53 protein, human
0
Tumor Suppressor Protein p53
0
Types de publication
Journal Article
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1132-1144Subventions
Organisme : Intramural NIH HHS
ID : ZIA CP010218
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Published by Elsevier B.V.
Déclaration de conflit d'intérêts
Conflict of interest The authors have no relevant affiliation or financial involvement with any organisation or entity with a financial interest in or financial conflict with the subject matter or materials discussed in this manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. Please refer to the accompanying ICMJE disclosure forms for further details.
Références
Nat Genet. 2015 Sep;47(9):1003-10
pubmed: 26258846
Nucleic Acids Res. 2019 Jan 8;47(D1):D994-D1004
pubmed: 30407583
Nat Rev Cancer. 2004 Sep;4(9):695-706
pubmed: 15343276
Nature. 2016 Sep 1;537(7618):63-68
pubmed: 27533040
Gastroenterology. 2017 Jul;153(1):249-262.e2
pubmed: 28363643
Ann Oncol. 2009 Jan;20(1):146-59
pubmed: 18667395
Nat Biotechnol. 2016 May;34(5):525-7
pubmed: 27043002
Nat Med. 2018 Oct;24(10):1550-1558
pubmed: 30127393
Nat Genet. 2015 Dec;47(12):1402-7
pubmed: 26551669
Gastroenterology. 2017 Aug;153(2):488-494.e1
pubmed: 28428144
J Hepatol. 2018 May;68(5):959-969
pubmed: 29360550
Nat Genet. 2014 Aug;46(8):872-6
pubmed: 24997986
Clin Cancer Res. 2016 Jun 15;22(12):2908-18
pubmed: 26787752
Br J Cancer. 2007 Dec 3;97(11):1577-82
pubmed: 18000509
Nat Genet. 2013 Dec;45(12):1470-1473
pubmed: 24185509
Cytokine. 2016 Jul;83:217-225
pubmed: 27173614
BMC Cancer. 2018 Mar 2;18(1):243
pubmed: 29499656
Tuberc Respir Dis (Seoul). 2016 Apr;79(2):85-90
pubmed: 27066085
Cell. 2010 Mar 19;140(6):871-82
pubmed: 20303877
Mol Cancer. 2019 Oct 17;18(1):145
pubmed: 31623628
JAMA. 2015 May 26;313(20):2075-7
pubmed: 26010638
Biochim Biophys Acta. 2016 Apr;1865(2):245-54
pubmed: 26980625
Int J Cancer. 2010 Sep 1;127(5):1011-20
pubmed: 20017137
Int J Cancer. 2013 Oct 1;133(7):1664-71
pubmed: 23504585
Nat Immunol. 2018 Feb;19(2):108-119
pubmed: 29348500
Nat Commun. 2019 Dec 2;10(1):5492
pubmed: 31792210
Nat Commun. 2018 Nov 8;9(1):4692
pubmed: 30410077
Cancer. 2019 May 1;125(9):1489-1498
pubmed: 30645774
Bioinformatics. 2003 Jan 22;19(2):185-93
pubmed: 12538238
Sci Rep. 2018 Apr 4;8(1):5671
pubmed: 29618736
Science. 2016 Dec 2;354(6316):1160-1165
pubmed: 27789795
Cancer Med. 2016 Nov;5(11):3310-3235
pubmed: 27726295
Gut. 2019 Jun;68(6):1024-1033
pubmed: 29954840
Cancer Discov. 2018 Feb;8(2):174-183
pubmed: 29247016
Nat Med. 2019 Mar;25(3):462-469
pubmed: 30742119